The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety concern was found to be unrelated ...
Novavax can move forward with a trial for its combined Covid-19 and influenza vaccine after regulators lifted a clinical hold ... plans to file for FDA approval of its own combo vaccine by ...
The lifted hold applies to Novavax’s flu ... combo vaccine. A trial participant who’d received the shot in Jan. 2023 later developed motor neuropathy, or muscle weakness, leading the FDA ...
Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.
Novavax Inc.’s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue.
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.
The FDA lifted its clinical hold on Novavax's COVID-flu vaccine trial. The hold was due to unrelated safety concerns, allowing trial resumption. Novavax aims for growth with its combination shot ...
Novavax (NASDAQ:NVAX) shares climbed 12% premarket on Monday after the U.S. FDA lifted clinical hold on the investigational new drug application for the pharma firm’s COVID-19-Influenza ...
(Reuters) -The U.S. Food and Drug Administration has lifted its clinical hold on ... combination shot and flu vaccine to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback